/images/ppid_59c68470-image-177068773220034130.webp)
What is the story about?
Shares of Aurobindo Pharma Ltd. will be in focus on Tuesday, February 10, as the company reported December quarter earnings that were largely ahead of estimates, while margins came in line.
The drugmaker posted a net profit of ₹909.8 crore, marginally below the CNBC-TV18 poll estimate of ₹929 crore, but up 7.5% year-on-year from ₹846 crore.
Revenue rose 8.4% YoY to ₹8,646 crore, comfortably beating the street estimate of ₹8,407 crore.
EBITDA for the quarter increased 12.4% YoY to ₹1,773.6 crore, compared with the poll estimate of ₹1,727 crore. Operating margins stood at 20.5%, in line with expectations and higher than 19.8% reported a year ago.
Growth during the quarter was driven by strong performance in Europe, where revenues climbed 27% YoY, while the ARV segment grew 22.5% YoY.
The US business also came in better than analyst estimates. R&D spending stood at 4.7% of sales, amounting to ₹409 crore.
The company's free cash flow came in at $118 million, with net cash at $251 million. Gross debt declined sequentially to $786 million from $843 million in the previous quarter.
Aurobindo Pharma shares settled 1.09% higher on Monday at ₹1,204, ahead of the earnings announcement. The stock has gained over 14% in the past six months.
The drugmaker posted a net profit of ₹909.8 crore, marginally below the CNBC-TV18 poll estimate of ₹929 crore, but up 7.5% year-on-year from ₹846 crore.
Revenue rose 8.4% YoY to ₹8,646 crore, comfortably beating the street estimate of ₹8,407 crore.
EBITDA for the quarter increased 12.4% YoY to ₹1,773.6 crore, compared with the poll estimate of ₹1,727 crore. Operating margins stood at 20.5%, in line with expectations and higher than 19.8% reported a year ago.
Growth during the quarter was driven by strong performance in Europe, where revenues climbed 27% YoY, while the ARV segment grew 22.5% YoY.
The US business also came in better than analyst estimates. R&D spending stood at 4.7% of sales, amounting to ₹409 crore.
The company's free cash flow came in at $118 million, with net cash at $251 million. Gross debt declined sequentially to $786 million from $843 million in the previous quarter.
Aurobindo Pharma shares settled 1.09% higher on Monday at ₹1,204, ahead of the earnings announcement. The stock has gained over 14% in the past six months.
/images/ppid_59c68470-image-177068503852327487.webp)
/images/ppid_59c68470-image-177068508630990142.webp)
